Desjardins, A., Peters, K. B., Vlahovic, G., Randazzo, D., Boulton, S., Massey, W. C., … Friedman, H. S. (2015). Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In Journal of Clinical Oncology (Vol. 33, pp. 2067–2067). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2067

Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.

Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, et al. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.

Desjardins, Annick, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2067–2067. Crossref, doi:10.1200/jco.2015.33.15_suppl.2067.

Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, Lipp ES, Herndon JE, Healy P, Miller E, Karmali RA, Friedman HS. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.